Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 491 Download: 23

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 2878 Download: 185 Crossref: 4

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 7760 Download: 610 Web of Science: 28 Crossref: 33

Editorial

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 3505 Download: 99 Web of Science: 5 Crossref: 5

Original Article

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts

Clin Mol Hepatol. 2021;27(1):207-218. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0115

View: 6226 Download: 247 Web of Science: 22 Crossref: 21

Editorial

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 3542 Download: 111 Web of Science: 4 Crossref: 3

Original Article

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um

Clin Mol Hepatol. 2016;22(3):382-389. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0047

View: 11961 Download: 201 Web of Science: 18 Crossref: 19

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2014;20(3):274-282. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.274

View: 6608 Download: 43 Web of Science: 3 Crossref: 2

The Korean Journal of Hepatology Elsewhere

Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B

Jeong Won Jang

Clin Mol Hepatol. 2010;16(3):342-346. Published online September 30, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.3.342

View: 5792 Download: 58 Crossref: 1

1

Predictors for virologic response in management of chronic hepatitis B

Jung Min Lee, M.D. Sang Hoon Ahn, M.D.-

Clin Mol Hepatol. 2010;16(1):1-4. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.1

View: 4075 Download: 27

3

Comparison of Lamivudine-induced HBsAg Loss rate according to age in children with chronic hepatitis B

Jung Mi Kim , Byung Ho Choe , Mi Ae Chu , Seung Man Cho

Clin Mol Hepatol. 2009;15(2):168-178. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.168

View: 4334 Download: 41 Crossref: 3

1

Prevalence and Clinical Implications of Occult Hepatitis B Virus Infection

Sung Won Cho

Clin Mol Hepatol. 2006;12(2):136-139. Published online January 1, 1970

View: 2637 Download: 17

1 |

Viewed By 5144	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5005	MAFLD: How is it different from NAFLD?
Viewed By 4914	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3640	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3582	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 67	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search